Alnylam Pharmaceuticals seeks an imaginative physician drug developer to provide clinical leadership in developing RNAi therapeutics across its neurology and hematology therapeutic area. The role’s primary focus is serving as a clinical study lead for the plasminogen program as it transitions from Phase 2 to Phase 3. The Director reports to the program clinical development strategy lead, who oversees clinical research for the program. The Director will help shape overall clinical development strategy and drive progress and operational excellence for clinical trials, working closely with external experts and internal teams across Regulatory, Biostatistics, Clinical Operations, Preclinical, Commercial, and Quality Assurance. The role also represents Alnylam Development at external meetings, including regulatory interactions and scientific meetings. Alnylam is a leader in RNAi therapeutics, a science-based approach with potential applications in rare and common diseases. The company describes its culture as focused on innovation, excellence, urgency, openness, inclusion, and commitment to people, and states that it is an equal opportunity employer. This full-time role has a U.S. base salary range of $255,000–$345,000. Compensation depends on factors including experience, skills, and education. The role is eligible for annual short- and long-term incentive awards, including bonus or sales incentive and equity. Benefits include medical, dental, and vision coverage; life and disability insurance; lifestyle reimbursement; flexible spending and health savings accounts; a 401(k) with company match; paid time off, wellness days, holidays, company-wide recharge breaks, and family resources and leave.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree